Clinical Study: Multiple Sclerosis

Back to Trials

If you are a healthy female aged between 18 and 55, then you may be eligible to participate in a study investigating a new drug being developed for the treatment of a condition called Multiple Sclerosis (MS).

Study Payment* £7,950.

Apply for this study

*Terms & Conditions apply.

Study Payment: £7,950

"*" indicates required fields

Step 1 of 3

This field is hidden when viewing the form

Advertising Source

* indicates a required field

By agreeing to this form and selecting the box as outlined below, you are confirming that you have read the information provided in our data protection and consent policy, and give your consent for Simbec-Orion to record and retain your personal and special categories of data for the purposes and duration(s) stated in our policy linked above.

Please confirm that you have read these terms and understand that Simbec-Orion will be holding and processing your personal and special categories of data for the purposes stated in our policy linked above.

Simbec-Orion are also required to process your bio-metric data (a photograph only when you attend an onsite screening visit), we do this to ensure we can identify you for security purposes. We do not share this data with any other third-party, we solely use this data for the purpose of recognition. For the completion of your enrolment and part of your eligibility, we are required to collect this data. By selecting the box below, you also explicitly consent to the use of your bio-metric data as and when it is collected.

Agreement*

I understand and wish to proceed

* indicates a required field

Your details

First Name*

Last Name*

Sex Assigned at Birth*

Date of Birth*

This field is hidden when viewing the form

Age

Height*

Weight*

Your BMI

This field is hidden when viewing the form

BMI Calc

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

Please register with our database as we may have studies in the near future which you may be eligible, register here This way we can be in contact as soon as you are eligible for another trial.

Race*

Your Race*

Street Address*

City*

Postcode*

Phone Number*

Email*

Can we contact you by email?

Yes

Can we contact you by SMS?

Yes

Can we contact you by phone?

Yes

Please select at least one contact mechanism to facilitate your participation in future clinical studies.

Study Information

Simbec-Orion Clinical Pharmacology will soon be running a study to investigate a new study drug being developed as a potential treatment for a condition known as Multiple Sclerosis (MS), which is a neurological condition in which the body’s immune system mistakenly attacks the protective lining surrounding nerve cells in the brain and spinal cord causing damage and inflammation.

The main objectives of the study are as follows:

To investigate if there are any interactions between the study drug and a combined oral contraceptive (the pill) and to evaluate if these interactions impact the levels of the study drug or the pill in the blood.

To investigate the safety of the study drug, and any side effects which may be associated with the study drug when it is given as multiple doses for up to 14 days.

If you participate in this study, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 22 days (21 overnight stays) and complete a post study follow-up visit on Day 30 (a minimum of 10 days following the last dose of study drug). Therefore, you should ensure that you are able to commit to completing all visits before agreeing to participate in this study.

Ready? Let’s get started

Purpose and Timeline

This study is classed as a drug-drug interaction study and will consist of up to 22 healthy female participants. This means that participants will be given a drug (combined oral contraceptive pill) which has known effects and a known method of breakdown in the body and also given the study drug to determine if there is any interaction between the drugs in the body and whether administration of the study drug affects the safety, tolerability and levels of the pill in the blood.

On Days 5-16, participants will take once daily doses of the study drug before taking a single dose of both the study drug and combined oral contraceptive pill together on Day 17 with the final dose of the study drug to be administered on Day 18. Each participant will receive the study drug and the combined oral contraceptive pill in the form of coated tablets which participants will swallow with water.

The treatment period for this study will require participants to stay overnight at the clinical unit for 21 overnight stays (from admission Day -1 to discharge Day 21). The treatment period is split into two parts and participants will remain in the clinical unit for the duration of both parts (1 and 2) of the treatment period.

Screening visit

Admission for the study is on Day -1 of Treatment Period Part 1. Discharge on day 21.

Post Study Follow-up Visit to be completed on Day 30.

If you complete this study, you will receive a maximum inconvenience payment of £7950.

Plus travel expenses.

Screening Visit
Day -35 to Day -2

Treatment Period Part 1

Day -1 to Day 5

Treatment Period Part 2

Day 5 to Day 21

Post Study Follow-up Visit

Day 30

Apply Now. Be Amazing

Clinical Study: Multiple Sclerosis

If you are a healthy female aged between 18 and 55, then you may be eligible to participate in a study investigating a new drug being developed for the treatment of a condition called Multiple Sclerosis (MS).

Study Payment* £7,950.

Your details

Study Information

Let's get started